ClinicalTrials.gg
CompletedNCT02028663Updated Aug 8, 2014

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

A Phase 2 interventional study of CJ-12420 and Esomeprazole in Erosive Esophagitis and GERD, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by HK inno.N Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
206
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Enrollment
11th of 52
206 · median 54
Started
2013
with 4 others
Phase 2
5 of 71
none open now
Registered
21st of 71
by date
Lead sponsor
4 of 71
HK inno.N Corporation

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 11th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2013, is one of 5 in phase 2, and was the 21st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.

03

Conditions studied

  • Erosive Esophagitis
  • GERD

Keywords

  • P-CAB
  • APA(Acid Pump Antagonist)
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 20-70
  • Diagnosed with Erosive Esophagitis by Esophagogastroduodenoscopy (EGD) and classified into LA Grade A to D within 14 days before randomization to treatment

Exclusion criteria

Exclusion Criteria:

  • Patients who cannot undergo EGD
  • Patients diagnosed with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected IBS
  • Patients who took PPIs within 2 weeks prior to study drug administration
  • Long-term use of nonsteroidal anti-inflammatory drugs throughout the study
  • abnormal laboratory values during screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
206 participants (actual)

Study arms

  • Experimental
    CJ-12420 Amg

    50 volunteers will be administered CJ-12420 Amg

    Drug: CJ-12420

  • Experimental
    CJ-12420 Bmg

    50 volunteers will be administered CJ-12420 Bmg

    Drug: CJ-12420

  • Experimental
    CJ-12420 Cmg

    50 volunteers will be administered CJ-12420 Cmg

    Drug: CJ-12420

  • Active comparator
    Esomeprazole 40mg

    50 volunteers will be administered Esomeprazole 40mg

    Drug: Esomeprazole

Interventions

  • Once daily, Oral administration

    Also known as: Undecided

  • Once daily, Oral administration

    Also known as: Nexium

06

What researchers measure

Primary outcomes

  1. Cumulative healing rate of erosive esophagitis at 8-week

    Time frame: 8 week

Secondary outcomes

  1. Healing rate of erosive esophagitis at 4-week

    Time frame: 4 week

07

Study locations

1 site
  • Seoul National University Hospital and 11 others
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2014
First posted
Jan 7, 2014
Start
May 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02028663
Responsible party
Sponsor
First posted
Jan 7, 2014
Start date
May 2013
Primary completion
May 2014
Completion
May 2014
Last update
Aug 8, 2014

Study contacts

Hyun-Chae Jung, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion